利伐沙班谷稳态Xa因子抑制可显著减少凝血酶生成
本研究在51例未接受抗凝治疗的非瓣膜性房颤患者中开展单中心、前瞻性、非随机、药物干预、自身对照研究,于利伐沙班治疗4周后谷稳态检测血浆浓度及凝血标志物。结果显示谷稳态平均利伐沙班浓度为23.6 ng/ml,F1+2、TAT和D-二聚体较基线下降,PT延长,TFPI在第一至第三四分位组升高,而PAI-1、蛋白C活性、蛋白S抗原和TM保持在正常范围。结论认为谷稳态残余利伐沙班可解释其抗凝血酶效应。
要点
- 利伐沙班谷稳态平均浓度23.6 ng/ml时,F1+2、TAT和D-二聚体较基线下降。
- 谷稳态PT较基线延长0.59秒,TFPI在第一至第三四分位组升高0.79 pg/ml。
- 谷稳态PAI-1、蛋白C活性、蛋白S抗原和TM保持在正常范围。
核心结论
- 谷稳态残余血浆利伐沙班可能解释非瓣膜性房颤患者的抗凝血酶效应。
研究设计与样本
- 单中心、前瞻性、非随机、药物干预、自身对照研究,纳入51例未接受抗凝治疗的非瓣膜性房颤患者。
- 利伐沙班治疗4周后于谷稳态检测血浆浓度及凝血相关标志物,并与基线比较。
主要发现
- LC-MS/MS与抗Xa显色法测得的血浆浓度相关(r=0.841,P<0.001)。
- 谷稳态平均利伐沙班浓度为23.6 ng/ml,F1+2较基线下降(P<0.0001),TAT下降(P=0.029),D-二聚体下降(P<0.005)。
- PT较基线延长0.59秒(P<0.0001)。
- TFPI在第一至第三四分位组从基线至谷稳态升高0.79 pg/ml(P=0.048)。
- PAI-1、蛋白C活性、蛋白S抗原和TM在谷稳态保持在正常范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of the present study was to demonstrate evidence of reduced thrombin generation at the trough plasma rivaroxaban concentration. METHODS: A single-centre, prospective, nonrandomized, drug-intervention, self-controlled study was conducted in 51 anticoagulation therapy-naïve patients with nonvalvular atrial fibrillation. Plasma rivaroxaban concentration was measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and the anti-factor Xa chromogenic assay. Partial thrombin time (PT), protein C activity, and protein S antigen, prothrombin fragment 1 + 2 (F1 + 2), D-dimer, thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasminogen activator inhibitor-1 (PAI-1) and tissue factor pathway inhibitor (TFPI) levels were also measured at the trough steady state after 4 weeks of rivaroxaban treatment and compared with baseline. RESULTS: Plasma concentrations obtained by the LC-MS/MS and anti-Xa assays were correlated (r = 0.841, P < 0.001). The mean concentration of rivaroxaban at the trough steady state was 23.6 ng ml-1 , at which F1 + 2, TAT and D-dimer had decreased from the baseline values (P < 0.0001, P = 0.029 and P < 0.005, respectively). PT was prolonged (+0.59 s, P < 0.0001). TFPI increased from baseline to the trough steady state in the first to third quartile groups (+0.79 pg ml-1 , P = 0.048). By contrast, PAI-1, protein C activity, protein S antigen and TM remained within the normal range at the trough steady state. CONCLUSIONS: Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation.
引用
- Horinaka S, Sugawara R, Yonezawa Y, et al. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation. Br J Clin Pharmacol. 2017. PMID: 28888219. doi:10.1111/bcp.13429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。